Smulders Y M, Thijs A
VU Medisch Centrum, afd. Algemene Inwendige Geneeskunde, Postbus 7057, 1007 MB Amsterdam.
Ned Tijdschr Geneeskd. 2006 Nov 11;150(45):2467-70.
Recently, a Dutch advisory committee to the Ministry of Health presented a report proposing criteria for health insurance coverage. A central role has been given to the criterion of cost per quality-adjusted life year (QALY) associated with medical interventions. The proposal is to limit the health-insurance coverage of such costs to 80,000 euro per QALY gained. Previously, 20,000 euro was generally considered a reasonable critical level for QALY-cost, whether for preventive or for curative interventions. Although a higher cut-off-level is now proposed by the advisory committee, recent cardiovascular prevention guidelines propose treatment criteria that are associated with much lower QALY costs, sometimes as low as 1,000 euro. With respect to financial considerations, the central role of QALY costs has been replaced in these prevention guidelines by national health budget implications. For individual patient care, these apparently opposing trends in the role and financial appreciation of QALYs have complex repercussions.
最近,荷兰卫生部的一个咨询委员会提交了一份报告,提议制定医疗保险覆盖标准。与医疗干预相关的每质量调整生命年(QALY)成本标准被赋予了核心地位。该提议是将此类成本的医疗保险覆盖限制在每获得一个QALY 80,000欧元。此前,无论对于预防性干预还是治疗性干预,20,000欧元通常被认为是QALY成本的合理临界水平。尽管咨询委员会现在提议提高临界水平,但最近的心血管疾病预防指南提出的治疗标准所涉及的QALY成本要低得多,有时低至1,000欧元。在财务考量方面,这些预防指南中,QALY成本的核心地位已被国家卫生预算影响所取代。对于个体患者护理而言,QALY在作用和财务评估方面这些明显相反的趋势产生了复杂的影响。